Blood Patents (Class 424/529)
-
Publication number: 20140271909Abstract: The disclosure relates to an apparatus for segregating particles on the basis of their ability to flow through a stepped passageway. At least some of the particles are unable to pass through a narrower passageway bounded by a segregating step, resulting in segregation of the particles. The breadth of the leading edge of at least one step of the apparatus is significantly greater than the overall width of the passageway in which the step occurs, permitting high and rapid sample throughput. The apparatus and methods described herein can be used to segregate particles of a wide variety of types. By way of example, they can be used to segregate circulating tumor cells from a human blood sample.Type: ApplicationFiled: November 12, 2013Publication date: September 18, 2014Inventor: George HVICHIA
-
Publication number: 20140242044Abstract: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive factor, for example biocompatible ceramics and glass.Type: ApplicationFiled: May 6, 2014Publication date: August 28, 2014Applicant: Kensey Nash BVF Technology LLCInventors: Douglas G. EVANS, Scott M. Goldman, Russell T. Kronengold
-
Patent number: 8815297Abstract: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of ?2 adrenergic receptors or need for increased 132 adrenergic receptor activity.Type: GrantFiled: March 31, 2010Date of Patent: August 26, 2014Assignee: Duke UniversityInventors: Jonathan S. Stamler, Liang Xie
-
Patent number: 8808753Abstract: The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 6, 2013Date of Patent: August 19, 2014Assignee: Stemnion, Inc.Inventors: Linda O Palladino, Vivienne S Marshall, Charlotte A Emig
-
Patent number: 8790722Abstract: The invention provides a composition for the prevention and inhibition of oxidative stress and hemolysis in human red blood cell wherein said composition compounds obtained from the aqueous stream of palm oil milling (palm oil vegetation liquor), in particular from vegetative liquor from the milling of palm oil fruit.Type: GrantFiled: September 11, 2008Date of Patent: July 29, 2014Assignee: Malaysian Palm Oil BoardInventors: Nagendran Balasundram, Ravigadevi Sambanthamurthi, Yew Ai Tan, Kalyana Sundram P. Manickam, Mohd Basri bin Wahid, Samir Samman, Nihal S. Agar
-
Patent number: 8785117Abstract: A bioartificial liver system is described that incorporates a cell reservoir and hepatocyte spheroids to both increase the number of and longevity of cells in the system. Additional methods are also described for forming spheroid aggregates from isolated hepatocytes.Type: GrantFiled: November 21, 2006Date of Patent: July 22, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventor: Scott L Nyberg
-
Publication number: 20140193379Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.Type: ApplicationFiled: January 8, 2014Publication date: July 10, 2014Applicant: United Therapeutics CorporationInventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
-
Publication number: 20140193512Abstract: Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site to complete clotting. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Applicant: Closys CorporationInventor: Karol L. Nowakowski
-
Patent number: 8765188Abstract: The invention relates to a composition comprising deer velvet antler blood (DVAB) in combination with velvet antler for use in the treatment and/or prevention of osteoporosis and a method for treating and/or preventing osteoporosis, comprising administering a therapeutically effective amount of a composition comprising DVAB and velvet antler to a subject at risk of developing or afflicted with osteoporosis. The composition of the invention, when administered to a subject with osteoporosis, increases anti-osteoporotic activity, decreases the biomarker of osteoporosis and recovers the biomechanical strength and structure of bone, suggesting that the said composition could significantly prevent and even treat osteoporosis.Type: GrantFiled: September 23, 2011Date of Patent: July 1, 2014Assignee: Taipei Medical UniversityInventors: Ching-Chiung Wang, Sung-Hui Tseng, Chun-Hsien Sung
-
Patent number: 8734854Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.Type: GrantFiled: July 9, 2009Date of Patent: May 27, 2014Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
-
Publication number: 20140134263Abstract: Methods and systems of processing exosomes from a biologic sample, including providing a biological sample having a mixed population of exosomes, wherein the mixed population of exosomes includes two or more distinct subpopulations of exosomes; and processing the biological sample to selectively remove one or more exosome subpopulations from the mixed population of exosomes thereby obtaining a sample enriched with a desired subpopulation of exosomes.Type: ApplicationFiled: November 13, 2013Publication date: May 15, 2014Inventor: Allan Yang Wu
-
Publication number: 20140134211Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations disclosed herein preferably include a blood component with a pharmaceutical agent. The blood component is preferably whole blood or platelet-rich plasma. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, triamcinolone hexacetonide, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4,), bisphosphonates, derivatives thereof, and combinations thereof. The formulations may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.Type: ApplicationFiled: April 8, 2011Publication date: May 15, 2014Inventor: James Louis RUTKOWSKI
-
Publication number: 20140127313Abstract: A pharmaceutical composition for preventing and treating HIV infection includes an active ingredient made by a process involving a series of intra- and inter-species blood transfers made among male and female animals. The process modifies the components of blood in the animals such that the blood from the last animal in the series of transfers can be used as the active ingredient in a pharmaceutical composition which, when administered to an HIV-infected human subject, can eliminate any detectable HIV in the subject.Type: ApplicationFiled: June 27, 2012Publication date: May 8, 2014Applicant: RONILU DEVELOPMENT CORPORATIONInventors: Roberto De Jesus Escobar-Gaviria, Nicolas Enrique Escobar-Urquijo, Luis Felipe Rodriguez-Sanchez
-
Publication number: 20140127312Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.Type: ApplicationFiled: December 5, 2013Publication date: May 8, 2014Applicant: University of British ColumbiaInventors: Jayachandran N. Kizhakkedathu, Rajesh A. Shenoi, Cedric J. Carter, Donald E. Brooks
-
Publication number: 20140121640Abstract: One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Peter J. Evans, Jim Trickett
-
Publication number: 20140112890Abstract: The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency.Type: ApplicationFiled: April 2, 2012Publication date: April 24, 2014Applicant: The John Hopkins UniversityInventors: Jennifer H. Elisseeff, Iossif Strehin
-
Publication number: 20140099293Abstract: A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin fragments are capable of triggering DNA damage leading to genomic instability, senescence, apoptosis and cancerous transformation of healthy cells on being integrated into their genomesType: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Tata Memorial CentreInventors: Indraneel MITTRA, Urmila Chandrashekhar SAMANT, Gopesh Kumar MODI, Pradyumna Kumar MISHRA, Gobichettipalayam Subbaratnam BHUVANESHWAR
-
Publication number: 20140083945Abstract: Focal segmental glomerulosclerosis (FSGS) is a common cause of proteinuric kidney disease, which comprises both native and transplanted kidneys. Treatment was limited in the past due to the complicated pathogenesis of FSGS, including previously unidentified serum factors. Here, serum soluble urokinase receptor (suPAR) is reported to be elevated in FSGS patients but not in patients with other primary glomerular diseases. Higher pre-transplantation suPAR levels are associated with risk for FSGS recurrence in kidney grafts. Renal disease only develops when suPAR sufficiently activates podocyte ?3 integrin. Thus, disease pathogenesis can be stopped or slowed by ex vivo removal of suPAR from a subject's circulation. Removal may be measured by comparing the level (e.g., amount or concentration) of suPAR before and after such treatment.Type: ApplicationFiled: May 9, 2012Publication date: March 27, 2014Inventor: Jochen Reiser
-
Patent number: 8673293Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.Type: GrantFiled: October 31, 2008Date of Patent: March 18, 2014Assignee: Universitat ZurichInventors: Roland Martin, Andreas Lutterotti, Stephen Miller
-
Publication number: 20140065237Abstract: The claimed product relates to the food industry, and specifically to biologically active food additives (BAA) for the prophylaxis of erectile dysfunction in men, produced on the basis of natural components. The essence of the claimed product consists in that a biologically active food additive for the prophylaxis of erectile dysfunction in men. The claimed additive includes L-arginine and drone brood, with the following ratio of ingredients: 50-96.2% by mass of L-arginine and 3.8-50% by mass of drone brood.Type: ApplicationFiled: April 10, 2012Publication date: March 6, 2014Inventors: Vyacheslav Nikolaevich Trifonov, Julia Anatoljevna Elistratova, Konstantin Gennadievich Elistratov, Natalie Vyacheslavovna Kurus
-
Publication number: 20140065150Abstract: Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 receptor (sFlt-1) antibody bound to a solid support in order to reduce blood levels of sFlt-1. Further disclosed are the sequences of the heavy chain and light chain CDRs of the anti-sFlt-1 antibodies.Type: ApplicationFiled: February 7, 2012Publication date: March 6, 2014Applicant: AGGAMIN PHARMACEUTICALS, LLCInventors: Paul Kussie, Woo S. Joo
-
Publication number: 20140065128Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.Type: ApplicationFiled: March 5, 2012Publication date: March 6, 2014Applicant: HANSA MEDICAL ABInventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
-
Patent number: 8652168Abstract: Wound closure methods and apparata are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparata for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.Type: GrantFiled: January 23, 2006Date of Patent: February 18, 2014Assignee: Closys CorporationInventor: Karol L. Nowakowski
-
Patent number: 8652169Abstract: Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.Type: GrantFiled: March 28, 2013Date of Patent: February 18, 2014Assignee: Closys CorporationInventor: Karol L Nowakowski
-
Patent number: 8632773Abstract: The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.Type: GrantFiled: March 26, 2010Date of Patent: January 21, 2014Assignees: CSL Behring AG, University of WashingtonInventors: Fabian Käsermann, Monika Rüegsegger, Sylvia Miescher, Keith Elkon
-
Patent number: 8617893Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.Type: GrantFiled: October 22, 2012Date of Patent: December 31, 2013Assignee: Cambridge Scientific Pty LtdInventors: Jeffrey D. Edwards, John Palermo
-
Publication number: 20130302342Abstract: The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.Type: ApplicationFiled: November 26, 2010Publication date: November 14, 2013Applicant: Evonik Roehm GmbHInventors: Benedikt Hartwig, Juan Tome Alcalde, Norbert Windhab, MarÃa del Pilar Ansuategui Panzano, MatÃas Javier Vara Carrera
-
Publication number: 20130295192Abstract: A system and method for identifying metabolic activity within the heart muscle (myocardium). Metabolic activity is determined through spectrographic analysis of the myocardium. More particularly, oxygen saturation of the myocardium is measured through the spectrographic analysis, and metabolic activity is measured by a decrease in oxygen saturation of the myocardium over time.Type: ApplicationFiled: April 1, 2013Publication date: November 7, 2013Inventors: Russel Hirsch, John Miras Racadio
-
Patent number: 8574860Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.Type: GrantFiled: May 9, 2012Date of Patent: November 5, 2013Assignee: University Health NetworkInventors: Eleftherios P. Diamandis, Chan-Kyung Jane Cho, Eduardo Martinez Morillo
-
Patent number: 8568448Abstract: Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.Type: GrantFiled: December 21, 2012Date of Patent: October 29, 2013Assignee: Closys CorporationInventor: Karol L Nowakowski
-
Publication number: 20130272999Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Publication number: 20130266577Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.Type: ApplicationFiled: March 4, 2013Publication date: October 10, 2013Inventor: Thomas Hunig
-
Publication number: 20130266549Abstract: The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting themogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.Type: ApplicationFiled: June 3, 2013Publication date: October 10, 2013Inventors: Abdellatif CHENITE, Amine SELMANI
-
Publication number: 20130259845Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.Type: ApplicationFiled: October 12, 2012Publication date: October 3, 2013Applicant: Anthrogenesis CorporationInventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
-
Publication number: 20130259951Abstract: A system for separating and concentrating a component of a whole material is disclosed. The whole material can include a material that has more than one component, such as whole blood that can include at least red blood cells, monocytes, and plasma. The system can include a substantially single container including a separation section and a concentration section wherein a component can be moved from the separation section, after a separation, to the concentration section to be concentrated. The concentrated component can then be withdrawn from the separation and concentration container for a selected procedure.Type: ApplicationFiled: March 29, 2012Publication date: October 3, 2013Applicant: Biomet Biologics, LLCInventor: Patrick S. O'Connell, JR.
-
Publication number: 20130251670Abstract: Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.Type: ApplicationFiled: September 13, 2012Publication date: September 26, 2013Applicant: Aidan Products, IncInventors: Neil H. Riordan, Jorge Paz Rodriguez
-
Publication number: 20130243743Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: ApplicationFiled: October 17, 2012Publication date: September 19, 2013Applicant: ACCELERON PHARMA, INC.Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
-
Patent number: 8535703Abstract: Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or by employing a biologic resurfacing mold, for example) into, or in the vicinity of, the anatomical tissue. Upon insertion within, or contact with, the anatomical tissue, the biological component/glue composition is designed to coagulate and solidify (or partially solidify) within minutes, to advance healing or tissue growth of the anatomical tissue. The biological component/glue composition may optionally comprise components such as growth factors, antiseptic chemicals and/or antibiotics and/or electrolytes, or hormones or site-specific hybrid proteins, among others.Type: GrantFiled: August 26, 2008Date of Patent: September 17, 2013Assignee: Arthrex, Inc.Inventors: Reinhold Schmieding, Gerlinde Michel, Stephane Naudin, Hans Linden
-
Publication number: 20130236559Abstract: A method and device for treating cholesterol disorders includes administering at least one treatment regime including two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels prior to treatment. Treatment according to the method results in decreased LDL levels in patients having abnormal LDL levels and increased HDL levels in patients having abnormal HDL levels. Each subsequent round of plasmapheresis is conducted weekly, but no more than twice per week.Type: ApplicationFiled: March 12, 2012Publication date: September 12, 2013Applicant: GRIFOLS, S.A.Inventors: Victor GRIFOLS LUCAS, Victor Grifols Roura
-
Patent number: 8529956Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: April 17, 2008Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Carnegie Mellon University, Allegheny-Singer Research InstituteInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529960Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529959Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529958Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529961Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8507629Abstract: A production method of the present invention is a production method of an organic polymer containing two or more organic ring structures and a chain structure threading through the organic ring structures. This method includes a polymerization step of forming the organic polymer, in which the organic ring structures, which are restricted from moving, are disposed at each of a particular constitutional unit, by polymerizing at least one type of monomers each of which has no ionic functional group that releases a metal ion. The above at least one type of monomers include a monomer (M) containing the organic ring structure and a chain component threading through the organic ring structure.Type: GrantFiled: December 6, 2007Date of Patent: August 13, 2013Assignee: Panasonic CorporationInventors: Takayuki Takeuchi, Norihisa Mino, Nobuaki Kambe, Jun Terao
-
Publication number: 20130189338Abstract: Demineralized bone matrix fibers and demineralized bone compositions are provided. Implantable demineralized bone matrix compositions include elongated bone fibers having an average length from about 2 cm to about 6 cm and an aspect ratio from about 50:1 to about 1000:1. The demineralized bone matrix compositions also include a carrier in an amount sufficient to produce a cohesive formable mass. The elongated fibers can easily entangle to provide an improved demineralized bone matrix having increased osteoconductivity.Type: ApplicationFiled: January 19, 2012Publication date: July 25, 2013Applicant: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Guobao Wei
-
Patent number: 8449922Abstract: A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating normal mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be administered subcutaneously. The effects of the treatment on the individual can be reflected by clinical tests such as hematological immunological profiles and symptom and signs scores.Type: GrantFiled: July 30, 1997Date of Patent: May 28, 2013Inventors: William James Rea, Bertie B. Griffiths
-
Publication number: 20130078311Abstract: The invention relates to a composition comprising deer velvet antler blood (DVAB) in combination with velvet antler for use in the treatment and/or prevention of osteoporosis and a method for treating and/or preventing osteoporosis, comprising administering a therapeutically effective amount of a composition comprising DVAB and velvet antler to a subject at risk of developing or afflicted with osteoporosis. The composition of the invention, when administered to a subject with osteoporosis, increases anti-osteoporotic activity, decreases the biomarker of osteoporosis and recovers the biomechanical strength and structure of bone, suggesting that the said composition could significantly prevent and even treat osteoporosis.Type: ApplicationFiled: September 23, 2011Publication date: March 28, 2013Inventors: CHING-CHIUNG WANG, SUNG-HUI TSENG, CHUN-HSIEN SUNG
-
Publication number: 20130078312Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.Type: ApplicationFiled: September 28, 2011Publication date: March 28, 2013Inventor: Vipin Kunjachan
-
Patent number: 8389016Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.Type: GrantFiled: October 14, 2008Date of Patent: March 5, 2013Assignee: Theramab LLCInventor: Thomas Hunig